Medical device company Vitrolife AB (STO:VITR) announced on Friday the receipt of market approval for the time-lapse incubator EmbryoScope+ in the US, considered the world's third largest market measured in terms of number of IVF treatments.
EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for 15 patients. Vitrolife is a market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos.
With this approval, Vitrolife will be able to offer EmbryoScope+ to clinics in US.
Vitrolife develops, produces and markets medical devices for assisted reproduction.
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system
Bonesupport shifts CERAMENT V review to FDA's De Novo pathway
Neola Medical secures US patent for disposable lung monitoring probes
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix